Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Kyu-pyo Kim"'
Autor:
J.H. Kim, Sun Young Chae, Sun Young Kim, Yong Sang Hong, Hwa Jung Kim, Jeong Eun Kim, Jin-Sook Ryu, Jae Seung Kim, Tae Won Kim, Kyu-Pyo Kim, Dae Hyuk Moon
Publikováno v:
Targeted Oncology. 14:689-697
Tyrosine kinase inhibitor-induced hypothyroidism is associated with favorable survival in patients with various cancers. We aimed to investigate the incidence of regorafenib-induced hypothyroidism and assess its prognostic value in patients with meta
Autor:
Yasutoshi Kuboki, Chia-Chi Lin, Kan Yonemori, Lwona Dobler, Tomoko Yanai, Farhad Sedarati, Toshio Shimizu, Kyu-Pyo Kim, Douglas V. Faller, Neeraj Gupta
Publikováno v:
Targeted oncology. 17(1)
Sapanisertib is an oral, highly selective inhibitor of mammalian target of rapamycin complexes 1 and 2. The aim of this study was to assess the safety, tolerability, pharmacokinetics, preliminary efficacy, and to establish the recommended phase 2 dos
Autor:
Toshio Shimizu, Yasutoshi Kuboki, Chia-Chi Lin, Kan Yonemori, Tomoko Yanai, Douglas V. Faller, lwona Dobler, Neeraj Gupta, Farhad Sedarati, Kyu-pyo Kim
Publikováno v:
Targeted Oncology. 17:377-377
Autor:
Baek-Yeol Ryoo, Sun Young Kim, Hee-Sang Hwang, Y.S. Hong, Seung-Mo Hong, Kyu-Pyo Kim, Tae Won Kim, Changhoon Yoo, Junho Kang
Publikováno v:
Investigational New Drugs. 37:763-770
Lanreotide autogel is a long-acting somatostatin analogue with proven efficacy and safety in patients with well-differentiated (WD) gastroenteropancreatic-neuroendocrine tumors (GEP-NETs) in a prior randomized phase III trial (CLARINET). However, the
Autor:
Jae Ho Jeong, Kyu-Pyo Kim, Inhwan Hwang, Changhoon Yoo, Heung-Moon Chang, Jihoon Kang, Hei Nga Natalie Ip, Baek-Yeol Ryoo
Publikováno v:
Investigational New Drugs. 37:584-590
Background Nab-paclitaxel plus gemcitabine (AG) is standard first-line chemotherapy for patients with metastatic pancreatic cancer (mPC). However, prognostic factors for patients with mPC treated with AG, are largely unknown. We retrospectively ident
Autor:
Gi-Won Song, Changhoon Yoo, Jae Hoon Lee, Kang Mo Kim, Kyu-Pyo Kim, Heung-Moon Chang, Hyungwoo Cho, Deok-Bog Moon, Ju Hyun Shim, Sung Koo Lee, Han Chu Lee, Myung-Hwan Kim, Young-Suk Lim, Young-Joo Lee, Sang Soo Lee, Tae Jun Song, Jae Ho Jeong, Baek-Yeol Ryoo, Shin Hwang, Jihoon Kang, Do Hyun Park
Publikováno v:
Investigational New Drugs. 36:496-502
Background We aimed to comprehensively evaluate the prognostic value of inflammation-based prognostic scores, including the modified Glasgow Prognostic Score (mGPS), neutrophil–lymphocyte ratio (NLR), and platelet–lymphocyte ratio (PLR), exclusiv
Autor:
Kyoung-Jin Park, Myung-Hwan Kim, Tae Jun Song, Dong Wan Seo, Jae Hoon Lee, Sang Hyun Shin, Do Hyun Park, Dae Wook Hwang, Sung Koo Lee, Song Cheol Kim, Heung-Moon Chang, Woochang Lee, Kyu-Pyo Kim, Sang Soo Lee, Tae Won Kim, Kyoungmin Lee, Changhoon Yoo, Ki Byung Song, Baek-Yeol Ryoo, Jae-Lyun Lee
Publikováno v:
Investigational New Drugs. 36:163-169
Introduction Germline BRCA mutations may have therapeutic implications as surrogate markers of DNA-damage repair status in pancreatic ductal adenocarcinoma (PDAC). We performed a prospective study to evaluate the efficiency of risk criteria based on
Autor:
Ki-Eun Choi, Sumi Park, Kyu-Pyo Kim, Younkyoung Kim, Kyun-Seop Bae, Jong Woo Chung, S.S. Kim, Yun Jung Choi, Tae Won Kim, MiYeon Park, Sung-Ho Beck, Young-Suk Lim
Publikováno v:
Therapeutic innovationregulatory science. 50(4)
Despite the fact that unaddressed delays in clinical trial operation could severely compromise the overall effort invested, there seems to be a lack of concerted effort in reforming such delays. This study evaluated the composite effect of initiative
Autor:
Soo Yeon Park, MiYeon Park, YooMi Lee, YunJeong In, Tae Won Kim, HyeJung Jeon, Yun Jung Choi, Ha Yeong Koo, Sinae Kim, S.S. Kim, Sumi Park, Kyu-Pyo Kim
Publikováno v:
Therapeutic innovationregulatory science. 49(2)
Delays in trial opening should be considered critical for the sake of not only the sponsor but the patients, as they may result in inequities of care. The Asan Medical Center, in Seoul, Korea, implemented a trial activation initiative in July 2012, i
Autor:
Sang Soo Lee, Jae Ho Jeong, Kyu-Pyo Kim, Sang Hyun Shin, Dong Wan Seo, Myung-Hwan Kim, Sung Koo Lee, Inhwan Hwang, Jihoon Kang, Seung-Mo Hong, Jae Hoon Lee, Heung-Moon Chang, Baek-Yeol Ryoo, Do Hyun Park, Changhoon Yoo, Ki Byung Song, Tae Jun Song, Dae Wook Hwang, Song Cheol Kim
Publikováno v:
Investigational new drugs. 36(4)
Purpose nab-paclitaxel plus gemcitabine (AG) and FOLFIRINOX have been established as standard first-line treatment in metastatic pancreatic cancer (mPC). We performed retrospective analysis comparing the efficacies of AG and FOLFIRINOX in daily pract